Angelini Pharma appoints new CEO
Angelini Pharma, part of the privately owned Italian industrial group Angelini Industries, has announced the appointment of Sergio Marullo di Condojanni as chief executive (CEO).
He has served as CEO of Angelini Industries since 2020 and will maintain that role while assuming leadership of the pharmaceutical division to drive cohesive strategy implementation, leveraging extensive executive, governance, and financial expertise. Jacopo Andreose, who led Angelini Pharma until the end of 2025, will become a member of the Angelini Holding board and a senior advisor to the Angelini Pharma board.
The appointment is part of Angelini Industries’ multi-year effort to strengthen its corporate governance and operating model, building on the Group's century-long heritage of pharmaceutical excellence. The transition aims to further solidify pharmaceutical healthcare as a core pillar of its long-term growth strategy alongside industrial technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze